Semaglutide is in clinical development for the treatment of overweight and obese adolescents
between the ages of 12 and 17. Obesity is a chronic disease and global public health challenge
and the prevalence of childhood obesity rising in the UK. Obesity increases the risk of developing
a range of health conditions in childhood and later life, including stroke, hypertension and type 2
diabetes.
Semaglutide for treating overweight and obesity in adolescents ages 12 to 17 years old
Semaglutide is in clinical development for the treatment of overweight and obese adolescents between the ages of 12 and 17.
Interventions:
Semaglutide (Ozempic)
Indications:
Obesity
Therapeutic Areas:
Endocrine Nutritional and Metabolic Disorders
Year:
2022